HK Stock Market Move | Biocytogen Pharmaceuticals-B(02315) rose over 12% and reached a strategic cooperation with Moonlight Bio. Net profit is expected to increase more than four times year on year last year.

Biocytogen Pharmaceuticals-B(02315) rose more than 12%, up 12.14% as of the time of writing, at HK$54.5, with a turnover of HK$160 million. On the news front, on March 23, Biocytogen Pharmaceuticals announced a strategic cooperation agreement with Moonlight Bio, Inc., a biotechnology company based in Seattle that specializes in cutting-edge cell therapy. The collaboration aims to develop a new generation of cell therapies to address various challenging and difficult-to-treat cancers. According to the agreement, Biocytogen Pharmaceuticals will provide full human antibody molecules targeting treatment targets, while Moonlight Bio will be responsible for the preclinical development work related to cell therapy. In addition, Biocytogen Pharmaceuticals previously released its 2025 performance report, expecting an annual revenue of approximately RMB 1.379 billion in 2025, a year-on-year increase of 40.63%; achieving a net profit attributable to owners of the company of RMB 173 million, a year-on-year increase of 416.37%. The growth in operating performance is mainly attributed to the continued expansion of overseas markets, coupled with the recovery of the domestic biopharmaceutical industry, resulting in rapid growth in group revenue.